VYNE Therapeutics

Update in progress

VYNE (NCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

VYNE Therapeutics is a clinical‑stage biopharmaceutical company developing therapies for chronic inflammatory and immune‑mediated diseases. Its lead program, repibresib gel (VYN201), is a topically applied soft drug BET inhibitor designed to reduce inflammation with low systemic exposure. VYN202 is a BD2‑selective oral BET inhibitor in Phase 1b for immune‑mediated conditions. Founded 2003, Stewartsville, New Jersey; formerly Menlo Therapeutics (renamed 2020).

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive